Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

An analysis of 2 pharmacovigilance databases revealed a high prevalence of azacitidine-related adverse events in patients with MDS or AML.

Geron could have a tougher time than it anticipated at tomorrow’s FDA advisory committee meeting for myelodysplastic syndromes (MDS ... points to a high risk of neutropenia and thrombocytopenia ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.

To their surprise, they found that as these mice aged, they developed anemia and excess of neutrophils and platelets in the blood. These exact features also occur in aged mice and people but were ...

Ovarian cancer's high incidence-fatality rate is due to late-stage diagnosis and lack of effective screening tools. An EHR-based symptom inventory was tested in a Colorado ob-gyn practice ...

Sep. 25, 2024 — People with Down syndrome face a higher risk of developing leukemia. Now researchers explain why, by identifying specific changes in blood cells of people with Down ...

A recent study has uncovered a potential breakthrough in treating osteonecrosis of the femoral head (ONFH), a debilitating bone disease that causes severe pain and joint collapse.

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.